Brava Diagnostics to Present at InnovatED Pitch Event at the American College of Emergency Physicians Scientific Assembly

First product is a high-sensitivity troponin point-of-care assay for chest pain assessment

 

Boulder, CO, October 15, 2019 – Brava Diagnostics, Inc., a Boulder, CO company transforming acute care diagnostics with a next generation point-of-care platform, is pleased to announce that the American College of Emergency Physicians Scientific Assembly (ACEP19) has selected Brava as one of only four medical device companies to participate in the InnovatED Pitch Event. Byron Hewett, CEO, will present at the Medical Device and Digital Health competition, held on Tuesday, October 29 from 11:45-12:30 at booth 1026 at the Colorado Convention Center in Denver. ACEP19 is the largest annual educational conference and tradeshow for emergency personnel in the world. https://www.acep.org/acep19/ AngelMD is the sponsor of the InnovatED Pitch Event. https://www.angelmd.co/en/

Rapid triage of patients presenting to the emergency department with chest pain is critical to saving lives and improving quality of care in the emergency department. In 2018, there were an estimated 8 million visits to U.S. emergency departments for chest pain, but 87% of them did not receive a diagnosis of heart attack. Brava Diagnostics is developing a highly sensitive and cost-effective evanescent planar waveguide technology to deliver rapid, simple and quantitative measurement of very low concentrations of troponin from whole blood. This combination is critical in acute care settings, where precision at low concentrations is imperative to inform immediate treatment decisions or to discharge safely.

Guidelines from the American College of Cardiology and the European Society of Cardiology are driving the shift to high-sensitivity troponin. Heart attack can be ruled-in 4-8 hours sooner than contemporary troponin assays because the biomarker can be measured earlier. In addition, the clinical utility of high sensitivity troponin in accelerated rule-out and safe discharge of low-risk patients was recently reported in the HiSTORIC study of 31,492 patients. Rapid rule-out eases crowding in the emergency department, reduces hospital admissions, improves patient satisfaction and can save the healthcare system billions of dollars annually. Brava’s point-of-care high sensitivity cardiac troponin test could accelerate discharge by an additional 30-45 minutes.

About Brava Diagnostics
Brava is developing a point-of-care high-sensitivity troponin test to assess patients with chest pain to guide treatment decisions or safe discharge. Unlike the central lab that takes 60-90 minutes to return results, the Brava test delivers lab-quality results in 15 minutes, which means faster rule-in of heart attack and faster rule-out and safe discharge of low-risk patients. Rapid rule-out eases crowding in the ED, reduces the number of admissions, improves resource utilization, improves patient satisfaction and reduces costs to the healthcare system.